Geron reports inducement grants as Geron stock trades at EUR 1.08
Published on 10/07/2026 at 08:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Geron stock (ISIN US3741631036) was trading at EUR 1.08 at Lang & Schwarz on October 7, 2026 at 8:08 a.m. CEST, down 0.92 percent versus the prior close of EUR 1.09. The company reported inducement grants on September 18, 2026, according to Geron.
Quarterly revenue beats estimates
Geron's second-quarter 2026 revenue was USD 57.48 million, compared with the USD 55.30 million consensus estimate, according to MarketBeat. The comparison shows commercial revenue momentum, but the earnings line remained difficult for the biotechnology company.
Geron reported a second-quarter net loss of USD 16.68 million and earnings per share of minus USD 0.02, versus a consensus estimate of minus USD 0.01, the same MarketBeat report said. Revenue therefore exceeded expectations while the per-share loss was wider than forecast.
Hold consensus meets large target gap
MarketBeat reported a consensus Hold rating and a USD 4.00 price target, alongside two Buy ratings, two Hold ratings and one Sell rating. The target is a stated analyst reference, not a forecast by this article, and it highlights the wide gap between the current euro quote and the analysts' dollar-based valuation.
Geron's lead medicine is RYTELO, or imetelstat, which is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes, according to Geron. The company is also studying imetelstat in myelofibrosis through a pivotal Phase 3 trial, leaving commercial execution and clinical development as separate valuation drivers.
Pre-market quote remains below prior close
Geron had a market capitalization of USD 776.2 million and a Nasdaq 52-week range of USD 1.04 to USD 2.01 as of October 6, 2026. The finance data showed a latest Nasdaq quote of USD 1.21 at the October 6 regular-session close, while the Lang & Schwarz euro indication was lower in the October 7 pre-market window.
The further course of trading is shown by the continuously updated real-time quote of Geron stock.
Geron stock facts
- Company: Geron Corporation
- ISIN: US3741631036
- Ticker: GERN
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of October 7, 2026, 8:08 a.m. CEST): EUR 1.08
- Change versus prior close: minus 0.92 percent
- Prior close Lang & Schwarz (October 6, 2026): EUR 1.09
- Market capitalization: USD 776.2 million (as of October 6, 2026)
- 52-week range: USD 1.04-2.01 (as of October 6, 2026)
- Sector / Industry: Healthcare / Biotechnology
